Impax announces results of IPX066 ADVANCE-PD and APEX-PD Phase III study against Parkinson's

Impax Pharmaceuticals, the branded products division of Impax Laboratories, Inc. (NASDAQ: IPXL), today announced that IPX066 ADVANCE-PD and APEX-PD Phase III clinical study data will be presented in Poster Sessions at the 15th International Congress of Parkinson's Disease and Movement Disorders Conference in Toronto, Canada, held from June 5 to June 9. 

IPX066 is an investigational extended release carbidopa-levodopa (CD-LD) product intended to treat the motor symptoms of Parkinson's disease.


Impax Pharmaceuticals


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
New research reveals a potent weapon against Parkinson's disease